Retension Pharmaceuticals, Inc. (RTSN) stock
RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)
Close on Nov 18, 2026Market cap $11.22MP/E –Yield –
Retension Pharmaceuticals EV/EBITDA
EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.
No ev/ebitda figures for Retension Pharmaceuticals
Retension Pharmaceuticals has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?